Regeneron Pharmaceuticals

(

REGN

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Regeneron Pharmaceuticals rose $2.46 (1.9%) to $132.17 on average volume. Throughout the day, 807,707 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 852,000 shares. The stock ranged in a price between $128.33-$132.34 after having opened the day at $130 as compared to the previous trading day's close of $129.71. Other companies within the Drugs industry that increased today were:

K-V Pharmaceutical Company

(

KV.A

), up 34.7%,

Complete Genomics

(

GNOM

), up 28.8%,

Medgenics

(

MDGN

), up 25.5%, and

ARCA biopharma

(

ABIO

), up 25.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $11.73 billion and is part of the

health care

sector. Shares are up 134% year to date as of the close of trading on Thursday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and poor profit margins.

On the negative front,

Delcath Systems

(

DCTH

), down 37%,

Rosetta Genomics

(

ROSG

), down 18.7%,

Vermillion

(

VRML

), down 18.4%, and

Prima Biomed Ltd. ADR

(

PBMD

), down 12.6%, were all losers within the drugs industry with

Herbalife

(

HLF

) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null